Literature DB >> 31799491

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition.

Maira P Campos1, Melissa Cohen2, Erika Von Euw3, Victor Velculescu4, Jennifer L Kujak5, Dylan Conklin3, Dorothy Hallberg4, Dennis J Slamon2, Julia Elvin6, Gottfried E Konecny2.   

Abstract

Entities:  

Year:  2018        PMID： 31799491     DOI： 10.1200/PO.18.00025

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  2 in total

1.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

2.  Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.

Authors:  Julie Niogret; Valentin Derangère; Corentin Richard; Lisa Nuttin; François Ghiringhelli; Laure Favier; Leila Bengrine Lefevre; Anthony Bergeron; Laurent Arnould; Romain Boidot
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.